Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.38 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8738071 | 0.83 | HSD17B10 (0.56) | HSD17B10CA12CA1CA2CA7 | |
| SCHEMBL6131843 | 0.81 | HSD17B10 (0.54) | HSD17B10CA12CA1CA2CA7 | |
| SCHEMBL696223 | 0.81 | HSD17B10 (0.54) | HSD17B10CA12CA1CA2CA7 | |
| SCHEMBL11652162 | 0.79 | HSD17B10 (0.52) | HSD17B10CA12CA1CA2CA7 | |
| SCHEMBL12021260 | 0.79 | HSD17B10 (0.52) | HSD17B10CA12CA1CA2CA7 | |
| SCHEMBL23841643 | 0.79 | HSD17B10 (0.52) | HSD17B10CA12CA1CA2CA7 | |
| SCHEMBL365736 | 0.79 | HSD17B10 (0.52) | HSD17B10CA12CA1CA2CA7 | |
| SCHEMBL92968 | 0.78 | CYP3A4 (0.48) | HSD17B10MEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL1605246 | 0.77 | TYR (0.56) | TYRMEN1KMT2AMAPTESR2 | |
| SCHEMBL31621229 | 0.76 | RECQL (0.43) | TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230054028-A1 | PD-L1 ANTAGONIST COMPOUND | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2023-02-23 | — | — | US | disclosed |
| EP-4083032-A1 | PD-L1 ANTAGONIST COMPOUND | Adlai Nortye Biopharma Co., Ltd. (CN) | 2022-11-02 | — | — | EP | disclosed |
| WO-2021129584-A1 | PD-L1 ANTAGONIST COMPOUND | 杭州阿诺生物医药科技有限公司 | 2021-07-01 | — | — | WO | disclosed |
| CN-104540826-B | Spiro-fused piperidine derivatives useful as inhibitors of extrarenal potassium channels | 默沙东公司 | 2018-04-20 | — | — | CN | disclosed |
| CN-104540826-A | Spiro-fused piperidine derivatives useful as inhibitors of extrarenal potassium channels | MERCK SHARP & DOHME | 2015-04-22 | — | — | CN | disclosed |
| CN-102459216-B | Inhibitors of renal outer medullary potassium channels | MERCK SHARP & DO | 2015-01-28 | — | — | CN | disclosed |
| US-8399436-B2 | N-pyrazolyl carboxamides as CRAC channel inhibitors | GLAXO GROUP LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-8399436-B2 | N-pyrazolyl carboxamides as CRAC channel inhibitors | GLAXO GROUP LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-8399436-B2 | N-pyrazolyl carboxamides as CRAC channel inhibitors | GLAXO GROUP LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| US-20080312286-A1 | Indanone Potentiators of Metabotropic Glutamate Receptors | MERCK SHARP & DOHME CORP. | 2008-12-18 | — | — | US | disclosed |
| EP-1778686-B1 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LTD (GB) | 2008-10-29 | — | — | EP | disclosed |
| CN-101006087-A | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER (US) | 2007-07-25 | — | — | CN | disclosed |
| CN-1993335-A | Indanone potentiators of metabotropic glutamate receptors | MERCK & CO INC (US) | 2007-07-04 | — | — | CN | disclosed |
| EP-1778686-A2 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | Pfizer Limited (GB) | 2007-05-02 | — | — | EP | disclosed |
| EP-1773792-A1 | INDANONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merck & Co., Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006018718-A2 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LIMITED (GB) | 2006-02-23 | — | — | WO | disclosed |
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. | 2006-02-16 | — | — | US | disclosed |
| WO-2006015158-A1 | INDANONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| CN-1167670-C | Aryl carboxylic acid and tetrazole derivant | - | 2004-09-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | HSD17B10 3207/4885CA12 4629/4885CA1 3905/4885 |
| US-20230054028-A1 | PD-L1 ANTAGONIST COMPOUND | CD274, PDCD1LG2, PDCD1 | HSD17B10 2667/4885CA12 3762/4885CA1 4701/4885 |
| US-20080312286-A1 | Indanone Potentiators of Metabotropic Glutamate Receptors | GRM2, GRIK2, GRM1 | HSD17B10 1932/4885CA12 4562/4885CA1 2632/4885 |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | ORAI1, TRPV1, CACNA1E | HSD17B10 3761/4885CA12 2179/4885CA1 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.